RegeneRx Receives Notice of Allowance for Patent for Tβ4 Eye Drop Formulation

ROCKVILLE, Md., Nov. 2, 2016, RGRX, /PRNewswire/ RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ( the Company or RegeneRx ), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a single unit dosage eye drop formulation containing Thymosin beta 4 (Tβ4). Tβ4 is the active pharmaceutical ingredient in RGN-259, RegeneRx s preservative-free eye drops currently in Phase 3 clinical trials. Claims covered


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: